CDK7 and neoplasm: We also explored the therapeutic potential of combining CDK7 inhibition with the widely prescribed antiandrogen enzalutamide and found additive tumour growth repression in vivo, likely mediated largely through CT7001’s potent repression of cell cycle progression.